Type 2 Diabetes
Conditions
Brief summary
Endothelial dysfunction (ED) has been suggested as a possible causal link between postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent trials demonstrated a reduction of cardiovascular events by treatment with the alpha glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions. We were interested whether patients with newly diagnosed type 2 diabetes showed postprandial ED and if so whether acarbose was able to improve this condition.
Interventions
DRUGacarbose
100 mg (tablets) t.i.d.
DRUGplacebo
one tablet t.i.d.
Sponsors
Technische Universität Dresden
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
35 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age 35-75 years * type 2 diabetes (newly diagnosed) * well glycemic control (HbA1c \</= 8.1) * leucocyte count \> 6.2 or hs CrP \> 1
Exclusion criteria
* hs CrP \> 10 * type 1 diabetes * previous treatment with antidiabetic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal | at baseline and after 20 weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal | at baseline and after 20 weeks of treatment |
Outcome results
None listed